Immix Biopharma is trading 5.15% lower at $7.92, alongside weakness in the biotech sector. - XBI was down 2.08% during the regular session; healthcare and biotechnology ETFs were reported lower premarket. - No new company-specific announcement explaining the October 23 decline surfaced in the search. - Broader risk-off sentiment, including elevated oil prices and geopolitical concerns, may be weighing on shares, but available evidence does not establish a single direct catalyst.